Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.

被引：0
|
作者：
Zurita, Amado J.
Tidwell, Rebecca Slack
Troncoso, Patricia
Chapin, Brian Francis
Harris, Deborah
Pisters, Louis L.
Araujo, John C.
Pettaway, Curtis Alvin
Aparicio, Ana
Tu, Shi-Ming
Papadopoulos, John N.
Wang, Jennifer
Logothetis, Christopher
Pagliaro, Lance C.
Davis, John W.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX 77030 USA
[3] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5078
引用
收藏
页数：2
相关论文
共 50 条
  • [21] INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.
    Chen, Ronald C.
    Karrison, Theodore
    Lawton, Colleen Anne
    Hall, William Adrian
    Borno, Hala
    Rosu, Mihaela
    Jani, Ashesh B.
    Schuster, David M.
    Seider, Michael J.
    Efstathiou, Jason A.
    Posadas, Edwin Melencio
    Nguyen, Paul L.
    Feng, Felix Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [22] Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303).
    Williams, Scott
    Davis, Ian D.
    Sweeney, Christopher
    Stockier, Martin R.
    Martin, Andrew James
    Hague, Wendy
    Coskinas, Xanthi
    Yip, Sonia
    Tu, Emily
    Lawrence, Nicola Jane
    McDermott, Ray
    Kelly, Paul J.
    Deignan, Olwyn
    Hughes, Simon
    Fonteyne, Valerie
    Tombal, Bertrand F.
    Nguyen, Paul L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Randomized trial of androgen deprivation therapy (ADT) plus enzalutamide (Arm A) versus ADT plus bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
    Vaishampayan, U. N.
    Heilbrun, L.
    Monk, P.
    Sonpavde, G.
    Tejwani, S.
    Heath, E. I.
    Fontana, J.
    Chinni, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC)
    Mckay, Rana R.
    Gray, Kathryn P.
    Hayes, Julia H.
    Bubley, Glenn J.
    Rosenberg, Jonathan E.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [25] A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).
    Haresh, K. P.
    Vjaters, Egils
    Castellano, Daniel
    Olmos, David
    Shore, Neal D.
    Nevalaita, Liina
    Testa, Isabella
    Kappeler, Christian
    Kuss, Iris
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-na⟨ve prostate cancer with bone metastasis
    Nozawa, Masahiro
    Inagaki, Takeshi
    Nagao, Kazuhiro
    Nishioka, Tsukasa
    Komura, Takahiro
    Esa, Atsunobu
    Kitagawa, Michio
    Imanishi, Masaaki
    Uekado, Yasunari
    Ogawa, Takatoshi
    Kajikawa, Hiroshi
    Uejima, Shigeya
    Matsuyama, Hideyasu
    Hara, Isao
    Uemura, Hirotsugu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 693 - 701
  • [27] OCOG-RATIONAL: A phase II randomized trial of optimal recurrence-directed therapy (RDT) without or with androgen-deprivation therapy (ADT) in radio-recurrent oligo-metastatic castrate sensitive prostate cancer (romCSPC).
    Tsakiridis, Theodoros
    Gouveia, Andre
    Mesci, Aruz
    Vavassis, Peter
    Berlin, Alejandro
    Morgan, Scott C.
    Perlis, Nathan
    Niazi, Tamim
    Thoms, John
    Hotte, Sebastien J.
    Wright, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS305 - TPS305
  • [28] Randomized phase II trial of docetaxel, with or without doxercalciferol, in advanced, androgen-independent prostate cancer
    Attia, S.
    Eickhoff, J.
    Wilding, G.
    Blank, J.
    Rezazadeh, H.
    Shevrin, D.
    Glode, M.
    Jumonville, A.
    Eastman, M.
    Liu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results
    Antonarakis, Emmanuel S.
    Kibel, Adam S.
    Adams, George
    Karsh, Lawrence Ivan
    Elfiky, Aymen
    Shore, Neal D.
    Vogelzang, Nicholas J.
    Corman, John M.
    Tyler, Robert Claude
    Mccoy, Candice
    Wang, Yang
    Sheikh, Nadeem A.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] A phase II RCT of high-dose vitamin D supplementation for androgen deprivation therapy (ADT)-induced bone loss among older prostate cancer (PCa) patients.
    Peppone, Luke Joseph
    Mustian, Karen Michelle
    Peoples, Anita Roselyn
    Kerns, Sarah L.
    Reschke, Jennifer E.
    Cole, Calvin
    Janelsins, Michelle Christine
    Asare, Matthew
    Kamen, Charles Stewart
    Culakova, Eva
    Zhang, Hong
    Fung, Chunkit
    Lin, Po-Ju
    Mohile, Supriya Gupta
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345